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Analysis of CD137 and CD137L Expression in Human Primary Tumor 
Tissues
Aim To assess the expression of CD137 and CD137L in human pri-
mary tumor tissues and their potential role in tumor immunity.
Methods Expression of CD137 and CD137L was assessed by im-
munohistochemistry in frozen sections of 12 human normal tissues, 
15 benign tumors of epithelial or mesenchymal origin (adenoma and 
leiomyoma), and 36 malignant tumors of epithelial origin (squamous 
cell carcinoma and adenocarcinoma). The expression of CD137L on 
9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 
colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by re-
verse transcription polymerase chain reaction. To analyze the role of 
CD137L expressed on tumor cells, we co-cultured tumor cells express-
ing CD137L with activated T lymphocytes expressing CD137 or with 
Chinese hamster ovary cells expressing CD137 and then detected by 
ELISA the levels of cytokines (IL-8, IFN-γ) secreted by tumor cells or 
activated T cells.
Results The expression of CD137 and CD137L was observed only in 
human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but 
not in normal tissues (0/12, 0/12). CD137 was expressed on the vessel 
walls within tumor tissues, whereas CD137L was expressed on tumor 
cells. The expression of CD137 and CD137L was more common in 
malignant tumors, especially in moderate or low-differentiated tumors. 
Furthermore, CD137L expression found on tumor cell lines was func-
tional because the ligation of CD137L on lung squamous carcinoma 
cells L78 with CD137 on T cells induced IFN-γ production by T cells, 
and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with 
CD137 triggered tumor cells to produce IL-8.
Conclusion CD137 and CD137L are expressed in different human 
primary tumor tissues, suggesting that they may influence the progres-
sion of tumors.
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CD137, a member of the tumor necrosis fac-
tor receptor family, is expressed primarily on 
activated T lymphocytes and natural killer cells 
(1,2). In contrast, its ligand CD137L is main-
ly expressed on antigen-presenting cells, such 
as mature dendritic cells, activated B cells, and 
macrophages (3,4). The co-stimulation through 
CD137/CD137L enhances T cell activation, 
promotes the rejection of cardiac allografts and 
skin transplants, and eradicates experimentally 
induced tumors in mice (5-10).
However, expression of human CD137 
and CD137L is not restricted to immune 
cells, and the functions of human CD137/
CD137L pathway are more complex than 
that of mice. Expression of CD137 protein 
has been verified in chondrocytes (11) and 
on blood vessel walls in primary malignant 
tumors (12). Expression of CD137L has also 
been found on several human carcinoma cell 
lines and its function has been analyzed in vi-
tro. On the one hand, CD137L expressed on 
carcinoma cells could function as a co-stim-
ulatory molecule of T cell activation for the 
production of cytokines, most notably in-
terferon-gamma (IFN-γ), in co-culture of T 
cells and tumor cells. On the other hand, in-
cubation of tumor cells expressing CD137L 
with a CD137-Ig fusion protein leads to the 
production of interleukin-8 (IL-8) of tumor 
cells (13).
Up to now, however, no studies have re-
ported the expression of CD137L in human 
primary tumors. Therefore, the aim of this 
study was to assess the expression of CD137 
and CD137L in human primary tumor tissues 
and their potential role in tumor immunity.
Materials and methods
Cell lines
Human tumor cell lines – HepG2.2.15 (he-
patocarcinoma integrated with whole hepa-
titis B virus genome), BEL7402 (hepatocar-
cinoma), HLE (hepatocarcinoma), HT29 
(colon adenocarcinoma), L78 (lung squa-
mous carcinoma), A2 (lung adenocarcino-
ma), U937 (histocytic lymphoma), HL60 
(promyelocytic leukemia), and ECV304 (em-
bryonic venous endotheliocytes) – were pur-
chased from Medical Science Institute of 
Shandong Province. H6 (colon carcinoma) 
tumor cell line was kindly provided by Pro-
fessor Jiayou Zhang from the University of 
Kentucky, USA.
To obtain Chinese hamster ovary (CHO) 
cells expressing membrane CD137, CD137-
CHO cells (CHO transfected with human 
CD137 gene) were transfected as follows: 
the recombinant CD137-pCDNA3 plasmid 
(containing human CD137 cDNA sequence) 
and pSV2-dhfr plasmid were co-transfected 
into dhfr-CHO cells by lipid-mediated trans-
fection. The positive clones were selected by 
400 μg/mL G418. Expression of human mem-
brane CD137 on dhfr-CHO cells was induced 
by raising the concentration of methotrexate. 
CD137 mRNA and protein were determined 
by reverse transcription polymerase chain re-
action (RT-PCR), immunocytochemistry, and 
flow cytometry (14).
Cell culture
Tumor cell lines U937, HL60, HLE, HT29, 
A2, and L78 were routinely cultured in Ro-
swell Park Memorial Institute medium 
(RPMI) 1640 supplemented with 10% fe-
tal calf serum (FCS; Hangzhou Sijiqing, Chi-
na) and 1% penicillin/streptomycin (Sigma, 
St. Louis, MO, USA); ECV304 and H6 were 
cultured in DMEM, and BEL7402 were cul-
tured in MEM with the same supplements; 
HepG2.2.15 were cultured in MEM supple-
mented with 10% FCS and 380 ng/mL G418 
(Sigma). CD137-CHO cells were cultured in 
F12 medium containing 10% FCS and G418. 
Human peripheral blood mononuclear cells 
were isolated from peripheral blood derived 
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from healthy donors by Ficoll density gradient 
centrifugation.
Surgical specimens
A total of 63 tissue specimens were obtained 
from patients who underwent operations at 
Qilu Hospital, Shandong University, China, 
from 2000 to 2004. Pathological diagnosis in-
cluding tumor differentiation grade was made 
according to the recent World Health Orga-
nization criteria for different tumors by clini-
cal pathologists (15-17). Malignant tumors 
were divided into three differentiation grades 
as follows: high differentiation, moderate dif-
ferentiation, and low differentiation. Twelve 
specimens of normal tissue were excised from 
patients who were initially suspected to have a 
tumor but were later diagnosed as healthy. The 
tissue types and tumor differentiation grades 
are presented in Table 1. This study was con-
ducted in full compliance with the nation-
al legislation and the ethical standards of the 
Chinese Medical Association. Informed con-
sent was obtained from all patients before the 
biopsy.
Determination of CD137 or CD137L expression by 
immunohistochemistry
Fresh tissue specimens were frozen for 1 hour 
after the biopsy, then 4-6 μm-thick frozen sec-
tions were prepared at -20°C and fixed in ac-
etone for 10 minutes at 4°C. Immunohisto-
chemical staining for CD137 or CD137L 
expression was performed using an ABC kit 
(Boshide Company, Wuhan, China) accord-
ing to the manufacturer’s instructions. The 
sections were exposed to 0.3% hydrogen per-
oxide-methanol solution to quench endog-
enous peroxidase activity. After a 30-minute 
pre-incubation with normal goat serum, sec-
tions were incubated with anti-CD137 mAbs 
(5 µg/mL, BD Pharmingen Inc., San Diego, 
CA, USA) or anti-CD137L mAbs (4 µg/ml, 
BD Pharmigen Inc.) for 30 minutes, followed 
by biotinylated goat anti-mouse IgG, and avi-
din-biotin-peroxidase complex; diaminobenzi-
dine (Boshide Company) was used as a peroxi-
dase substrate. All incubations were performed 
at room temperature. As negative control, 
primary mAb was replaced with an isotype-
matched antibody with irrelevant specificity. 
Three random sections were examined.
Expression of CD137 or CD137L was as-
sessed by two independent pathologists who 
were blinded to the patient’s outcome. The 
immunoreactivity results were presented as 
either “negative” (percentage of CD137 or 
CD137L staining was 0%-10%) or “positive” 
(percentage of CD137 or CD137L staining 
was >10%).
Assessment of CD137L expression by RT-PCR
CD137L mRNA expression in various cells 
was detected using RT-PCR. Briefly, to-
tal RNA was extracted from the cells using 
TRIZOL (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. 
cDNA was synthesized using Superscript pre-
amplification system (Promega, Madison 
Table 1. Tissue types and differentiation grades of the tumors 
(n = 63)*
No. of specimens
Tissue type Total HD (n = 20) MLD (n = 16)
Malignant tumors (n = 36):
 Squamous cell carcinoma: 14  8  6
  lung  3  0  3
  nasal cavity  1  0  1
  esophagus  6  5  1
  cervix  4  3  1
 Adenocarcinoma: 22 12 10
  stomach  3  3  0
  colon  4  2  2
  rectum  4  2  2
  gallbladder  4  2  2
  pancreas  3  1  2
  breast  4  2  2
Benign tumors (n = 15):
  lung adenoma  3
  ovarian serous cystadenoma  2
  uterine leiomyoma  6
  thyroid adenoma  4
Normal tissues (n = 12):
  lung  3
  stomach  2
  colon  4
  breast  3
*Abbreviations: HD – high differentiation; MLD – moderate or low differentiation.
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WI, USA) and PCR amplification was per-
formed using the following primers (designed 
based on literature and synthesized by Shang-
hai Shenggong, China): human β-actin sense 
primer: 5‘ACA CTG TGC CCA TCT ACG 
AGG GG 3′; anti-sense primer: 5‘ATG ATG 
GAG TTG AAG GTA GTT TCG TGG 
AT 3′, human CD137L sense primer: 5‘GTT 
TCA CTT GCG CTG CAC CTG CAG 
CCA CTG 3′; anti-sense primer: 5‘GGC 
TCT AGA TAT CAA GGT CCA ACT 
TGG GA AGG 3′. After denaturation at 94°C 
for 5 minutes, 30 PCR cycles were performed 
using human CD137L specific primers, each 
consisting of a denaturation step (94°C, 1 
minute), an annealing step (52°C, 2 minutes), 
and an elongation step (72°C, 2 minutes), fol-
lowed by an extension at 72°C for 5 minutes. 
The products were detected by electropho-
resis on 2% agarose gel containing ethidium 
bromide and analyzed using Imagemaster Gel 
Analysis Software (Amersham Pharmacia Bio-
tech, Uppsala, Sweden). The expression levels 
of CD137L mRNA were compared after nor-
malizing OD value to β-actin, which was de-
fined as the ratio of ODCD137L/ODβ-actin.
Measurement of cytokines by ELISA
T cells were purified from peripheral blood us-
ing RosettesepTM Antibody Cocktail (Senx-
iong Company, Shanghai, China). Briefly, 250 
μL of RosetteSepTM cocktail was added per 5 
mL of peripheral blood, mixed, and incubat-
ed at room temperature for 20 minutes. Next, 
the sample was diluted with phosphate buffer 
saline containing 2% FCS. The diluted sam-
ple was then layered on top of Ficoll-Paque 
at a 1:2 dilution and then centrifuged for 20 
minutes at 2000 r/min at room temperature. 
Enriched T cells were harvested from the plas-
ma-Ficoll interface and washed twice with 
phosphate buffer saline containing 2% FCS. 
The purity of T cells detected by flow cytom-
etry was >95%.
Tumor cells L78 or HepG2.2.15 were cul-
tured in 96-well plates at 37°C, 5% CO2 in a 
volume of 200 μL with different concentra-
tion (1 × 106/mL, 5 × 105/mL, 1 × 105/mL), 
respectively. After 48 hours the supernatant 
was discarded, purified T cells (5 × 105/mL) 
were added in a volume of 200 μL in the pres-
ence or absence of anti-CD3 mAb (10 μg/mL, 
BD Pharmingen), or with anti-CD137L mAb 
(5 μg/mL, BD Pharmingen). After incubation 
for 48 hours, the supernatant was collected 
and IFN-γ was detected by enzyme-linked im-
munosorbent assay (ELISA) according to the 
manufacturer’s instructions (Senxiong Com-
pany). Briefly, the supernatant was added into 
96-well plates coated with anti-IFN-γ anti-
body in duplicate and incubated at 37°C for 
2 hours. Human recombinant IFN-γ was in-
cluded as standard. After six washes, biotinyl-
ated anti-IFN-γ antibody was added and incu-
bated at 37°C for 1 hour; avidin-conjugated 
horseradish peroxidase (HRP) was added for 
an additional 1 hour at 37°C, followed by the 
substrate working solution until color devel-
opment. Six phosphate buffer saline wash-
es were performed between steps, and plates 
were read at OD 492 nm using an automat-
ed microtiter plate reader (Bio-Rad, Hercules, 
CA, USA).
CD137-CHO cells expressing human 
CD137 (5 × 104/mL) were cultured in 96-well 
plate in a volume of 200 μL. After 24 hours 
the supernatant was discarded and 200 μL of 
tumor cells A2 and HepG2.2.15 (5 × 104/mL) 
was added. After incubation for 16-18 hours, 
the supernatant was collected and IL-8 was de-
termined by ELISA according to the manufac-
turer’s guidelines (Senxiong Company).
Statistical analysis
The t test and ANOVA (Turkey-Kramer mul-
tiple comparisons test) were used to assess 
the statistical significance. P<0.050 was con-
sidered significant. All calculations were per-
Croat Med J 2008;49:192-200
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formed using the Statistical Package for the 
Social Sciences (SPSS Inc., Chicago, IL, USA).
Results
Human primary tumor tissues express CD137 and 
CD137L at different locations
Both CD137 and CD137L expression was 
detected in human benign or malignant tu-
mor tissues but not in normal tissues (Table 
2). CD137L was expressed on tumor cells, 
whereas CD137 was detected on endothelial 
cells and smooth muscle cells of tumor vessel 
walls (Figure 1). In addition, tumors express-
ing CD137 also expressed CD137L, where-
as some tumors expressing CD137L did not 
show detectable CD137 (Table 2). Though 
the samples were derived from many different 
tissue types, expression of CD137 or CD137L 
was more often found in malignant tumors, 
especially in moderate or low-differentiated 
tumors. Only a few benign tumors expressed 
CD137 and CD137L, as opposed to about a 
half of malignant tumors (Table 3). Among 
malignant tumors, CD137 or CD137L ex-
pression in moderate or low-differentiated ma-
lignant tumors was higher than in highly dif-
ferentiated tumors.
Human tumor cell lines express high levels of 
CD137L
Our results showed that tumor cells in human 
primary tumor tissues expressed CD137L. We 
also detected CD137L expression in human 
Figure 1. Expression of CD137 or CD137L in human primary tumor tissues by immunohistochemistry. Within tumor tissues, CD137 was only 
expressed on the vessel walls including endothelial cells and smooth muscle cells, whereas CD137L was only expressed on the tumor cells. (A) 
Expression of CD137 and CD137L in thyroid adenoma. (B) Expression of CD137 and CD137L in rectal cancer. (C) Expression of CD137 and CD137L 
in breast cancer.
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tumor cell lines derived from different prima-
ry tissues by RT-PCR. Normal unstimulated 
peripheral blood mononuclear cells did not 
express CD137L mRNA but all investigat-
ed tumor cell lines (HepG2.2.15, BEL7402, 
HLE, HT29, L78, A2, U937, HL60, and 
H6) showed high levels of CD137L expres-
sion (Figure 2). Unexpectedly, non-tumor 
cell line, embryonic venous endotheliocytes 
ECV304, also expressed CD137L. These re-
sults indicated that CD137L was not only ex-
pressed in primary tumors but also in tumor 
cell lines and some non-tumor cell lines, sug-
gesting CD137L expression may be related to 
rapid cell growth.
CD137L expressed on tumor cells is functional
To investigate the role of CD137L on tu-
mor cells, we co-cultured tumor cells L78 or 
HepG2.2.15 expressing CD137L with acti-
vated human T cells in the presence of anti-
CD3 mAb to stimulate T cell to express 
CD137. We detected IFN-γ secreted by T 
cells using ELISA. In the presence of anti-
CD3 mAb, CD137-expressing T cells co-cul-
tured with L78 cells produced higher levels 
of IFN-γ than CD137-lacking T cells (in the 
absence of anti-CD3 mAb) (P<0.001), de-
pending on the tumor cell number (data not 
shown). After blocking CD137/CD137L 
pathway using anti-CD137L mAb, the levels 
of IFN-γ significantly decreased (P<0.001), 
compared with control IgG. However, there 
was no obvious change of IFN-γ secretion 
when T cells were incubated with or with-
out HepG2.2.15 cells (in the presence or ab-
sence of anti-CD3 mAb) (P = 0.375) (Figure 
3). This suggests that CD137L on L78 cells 
could conduct a co-stimulatory signal into 
T cells and this action could be specifically 
blocked by anti-CD137L mAb.
To confirm whether CD137L expressed 
on tumor cells could also signal back into 
Table 2. Status of CD137 and CD137L expression in benign and 
malignant tumors*
Differentiation CD137/CD137L pattern No. of
Tumor grade +/+ +/− −/+ −/− specimens
Lung adenoma  / 0 0 0 3 3
Ovarian serous 
cystadenoma
 / 0 0 0 2 2
Uterine leiomyoma  / 1 0 0 5 6
Thyroid adenoma  / 1 0 1 2 4
Lung squamous HD 0 0 0 0 0
 cell carcinoma MLD 3 0 0 0 3
Nasal cavity 
 squamous
HD 0 0 0 0 0
 cell carcinoma MLD 1 0 0 0 1
Esophageal 
 squamous
HD 1 0 1 3 5
 cell carcinoma MLD 1 0 0 0 1
Cervical squamous HD 1 0 1 1 3
 cell carcinoma MLD 0 0 0 1 1
Stomach HD 0 0 1 2 3
 adenocarcinoma MLD 0 0 0 0 0
Colonic HD 1 0 0 1 2
 adenocarcinoma MLD 1 0 0 1 2
Rectal HD 0 0 1 1 2
 adenocarcinoma MLD 2 0 0 0 2
Gallbladder HD 0 0 0 2 2
 adenocarcinoma MLD 1 0 1 0 2
Pancreatic HD 0 0 1 0 1
 adenocarcinoma MLD 1 0 0 1 2
Breast HD 1 0 0 1 2
 adenocarcinoma MLD 1 0 0 1 2
*Abbreviations: HD – high differentiation; MLD – moderate or low differentiation.
Table 3. Summary of CD137 and CD137L expression in normal 
or tumor specimens
No. of specimens
Tissue specimens Total CD137 CD137L
Normal tissues 12  0  0
Benign tumors 15  2  3
Malignant tumors: 36 15 21
 high differentiation 20  4  9
 moderate or low differentiation 16 11 12
Figure 2. Expression of CD137L mRNA on tumor cell lines. (A) CD137L 
mRNA expression on normal unstimulated peripheral blood mononuclear 
cells (PBMC), normal embryonic cell line (ECV304), and various tumor cell 
lines was detected by reverse transcription polymerase chain reaction. 
Lanes: 1 – PBMC; 2 – ECV 304; 3 – L78; 4 – BEL7402; 5 – HepG2.2.15; 6 
– HL60; 7 – A2; 8 – HLE; 9 – HT29; 10 – H6; 11 – U937. (B) CD137L mRNA 
levels were normalized to β-actin mRNA.
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tumor cells, HepG2.2.15, or A2 cells were 
co-cultured with fixed CD137-CHO cells 
expressing CD137, respectively, and IL-
8 in the supernatant was detected by ELI-
SA. Ligation of CD137L on tumor cells by 
CD137 expressed on CD137-CHO cells 
elevated the levels of IL-8 produced by 
HepG2.2.15 cells (P = 0.038). However, 
the action of CD137L on A2 cells was weak 
(Figure 4).
Discussion
We showed that both CD137 and CD137L 
were simultaneously expressed in human pri-
mary tumor tissues, but on different locations. 
CD137 was expressed on the vessel walls in 
tumor tissues, whereas CD137L was expressed 
on tumor cells. The expression of CD137 and 
CD137L was more common in malignant tu-
mors, especially in moderate or low-differen-
tiated tumors. Furthermore, we found that 
CD137L expressed on tumor cells was func-
tional in several ways. On the one hand, liga-
tion of CD137L on lung squamous carcinoma 
cells L78 with CD137 on T cells caused T cells 
to produce high levels of IFN-γ. On the other 
hand, ligation of CD137L on hepatocarcino-
ma cells HepG2.2.15 with CD137 caused tu-
mor cells to produce IL-8.
The CD137/CD137L pathway provides 
an important co-stimulatory signal for the ac-
tivation and proliferation of T cells as well as 
a reverse signal for IL-8 production by macro-
phages or tumor cells (6,18-22). Ligation of 
the CD137 molecule with CD137L or anti-
CD137 antibody can stimulate the activation 
and proliferation of CD4+ and CD8+ T cells 
in vitro. In mice model, administration of 
anti-CD137 antibody eradicates experimen-
tally induced tumors and CD137L on the 
tumor cell line or CD137L fusion proteins 
stimulates an effective anti-tumor immunity, 
suggesting that CD137L may be a target mol-
ecule for tumor therapy (8,9,23,24). To the 
best of our knowledge, our results are the first 
demonstration that human primary tumor 
tissues express CD137L and that low-differ-
entiated malignant tumor tissues show a high 
rate of CD137L, while normal tissues do not. 
Our results and Salih’s report (13) also indi-
cate that CD137L is constitutively expressed 
on carcinoma cell line. Although CD137L 
on tumor cells L78 could enhance IFN-γ se-
cretion by T cells, its action was weak. Nota-
Figure 4. Effect of CD137L on tumor cells on IL-8 secretion by tu-
mor cells themselves. CD137-CHO cells expressing human CD137 
(5 × 104/mL) were cultured in 96-well plate in a volume of 200 μL, after 
24 hours the supernatant was discarded and 200 μL of tumor cells 
A2, HepG2.2.15 (5 × 104/mL) were added, respectively. After incuba-
tion for 16-18 hours, the supernatant was collected and IL-8 was de-
termined by enzyme-linked immunosorbent assay. The results were 
shown as means ± standard error of the mean of three independent 
experiments. Open bars – tumor cells; closed bars – tumor cells + 
CD137-CHO cells.
Figure 3. Effect of CD137L on tumor cells on interferon-gamma (IFN-γ) se-
cretion by T cells. Tumor cells L78 or HepG2.2.15 (1 × 106/mL) were cultured 
in 96-well plates at 37°C, 5% CO2 in a volume of 200 μL. After 48 hours 
the supernatant was discarded, purified T cells (5 × 105/ml) were added in a 
volume of 200 μL in the presence or absence of anti-CD3 mAb, or with anti-
CD137L mAb. After incubation for 48 hours, the supernatant was collected 
and IFN-γ was detected by enzyme-linked immunosorbent assay (ELISA). 
The results are shown as means ± standard error of the mean of four inde-
pendent experiments. Plus indicates that the culture system contains the 
indicated cells or antibodies. Minus indicates that the culture system lacks 
the indicated cells or antibodies.
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bly, CD137L on tumor cells HepG2.2.15 also 
triggered them to produce IL-8. As a multi-
functional cytokine, IL-8 is initially charac-
terized for its leukocyte chemotactic activity 
but now is known to possess tumorigenic and 
proangiogenic properties as well. IL-8 is crit-
ical to the development and progression of 
numerous malignancies through angiogene-
sis (25). Therefore, whether human CD137L 
can be a target molecule for tumor therapy 
and what is the influence of CD137L on T 
cell-tumor cell interaction in vivo remains to 
be clarified.
Although CD137 and CD137L were of-
ten simultaneously expressed in the same tu-
mor tissue samples, their expression locations 
were different. CD137L was expressed on tu-
mor cells, while CD137 was expressed on en-
dothelial cells or smooth muscle cells of the 
vessel walls within tumor tissues, which is 
consistent with the previous report by Broll et 
al (12). However, the significance of CD137 
in tumor tissues is unknown. Broll et al (12) 
speculated that CD137 on the endothelium 
could cause monocyte activation and may 
contribute to monocyte extravasation into 
the tissue. We propose the hypothesis that 
the interaction of CD137 on the endothe-
lium with CD137L on tumor cells may pro-
mote tumor progression based on the follow-
ing evidence. First, CD137L on some tumor 
cells could trigger tumor cells to produce IL-
8, which is critical for the development and 
progression of numerous malignancies (25). 
Second, CD137 and CD137L were only ex-
pressed in benign or malignant tumors simul-
taneously but not in normal tissues, and their 
expressions were more common in malignant 
tumors, especially in moderate or low-differ-
entiated tumors. However, more investigation 
remains to be done.
Taken together, we demonstrated that the 
expression of CD137 and CD137L was ob-
served only in human benign or malignant 
tumors but not in normal tissues. CD137 
was expressed on the vessel walls within tu-
mor tissues, whereas CD137L was expressed 
on tumor cells. The expression of CD137 and 
CD137L was more common in malignant tu-
mors, especially in moderate or low-differen-
tiated tumors. Furthermore, we found that 
CD137L expressed on tumor cells was func-
tional. These data suggest that CD137 and 
CD137L expressed in human tumor tissues 
may influence tumor immunity during its pro-
gression.
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